PHI-101 is under clinical development by Pharos iBio and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PHI-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PHI-101 overview

PHI-101 is under development for the treatment of relapsed and refractory acute myelocytic leukemia and triple-negative breast cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It acts by targeting Fms-like tyrosine kinase 3 (FLT3). It is developed based on artificial intelligence (AI) technology. The drug candidate was also under development for the treatment of myelodysplastic syndrome. It is administered through oral route.

Pharos iBio overview

Pharos iBio is a biotech company that develop new drugs for orphan and rare diseases by using technology. The company is headquartered in Anyang-si, Gyeonggi-do, Republic of South Korea.

For a complete picture of PHI-101’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.